How LCAPP Will Shape the Future of Cardiac Care

LCAPP - Potential Clinical Indications

[Linear Cardiac Assist Pulsatile Pump]

LCAPP Deployment

LCAPP can be deployed or reconstrained in less than 2 minutes

LCAPP - In-Vivo Outcomes

Reduction:

Improved:

Increased:

No Reduction:

In-vivo data demonstrates how LCAPP unloads the heart

Features	LCAPP	Abiomed/Impella LV Rotary Pump	Cardio-Renal Rotary Pump⁺	Balloon Pump
Pump Speed	150-325 CPM	33,000-45,000 RPM	8,000-20,000 RPM	40-180 CPM
Pump Output	3.5-7.0 LPM	2.5-3.5 LPM	3.0-6.0 LPM	0.5-1.5 LPM
Pulsatile Positive Displacement Pump	Yes	No	No	Yes
Precision ECG Gating	Yes	No	No	Yes
Afterload Sensitivity	No	Yes	Yes	No
Cardio-Renal Application	Yes	No	Yes	No
Risk of Hemolysis	Low	High	High	Low
Time of Implant/Explant	~1-2 mins	~22 mins	~10-30 mins	~15 mins
Requires Aortic Valve Crossing	No	Yes	No	No

⁺These products include Procyrion's Aortix, Second Heart Assist, Magenta Medical's Elevate, and Puzzle Medical's ModulHeart.

SummaCor has built a picket fence around the linear cardiac assist space

Title	Application No.	Patent No.	Number of Claims	Status	Country
Linear Cardiac Assist Pulsatile Pump	18/459,308	11,839,708	96	Issued	United States of America
Linear Cardiac Assist Pulsatile Pump	18/459,315	12,017,055	30	Issued	United States of America
Linear Cardiac Assist Pulsatile Pump	N/A	7549384	30	Issued	Japan
Linear Cardiac Assist Pulsatile Pump	17/073,085		118	Allowed	United States of America^*
Linear Cardiac Assist Pulsatile Pump	17/676,025		99	Published	United States of America^*

^*Corresponding foreign applications also filed in Australia, Canada, Europe, and Japan